
Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Drugs In Development, 2022, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.
Dyslipidemia is defined as elevation of the total cholesterol, the bad low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the good high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 34, 21, 27, 3, 38, 16 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 4 molecules, respectively.
Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Drugs In Development, 2022, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.
Dyslipidemia is defined as elevation of the total cholesterol, the bad low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the good high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 34, 21, 27, 3, 38, 16 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 4 molecules, respectively.
Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
328 Pages
- Introduction
- Global Markets Direct Report Coverage
- Dyslipidemia – Overview
- Dyslipidemia – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Dyslipidemia – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Dyslipidemia – Companies Involved in Therapeutics Development
- 89bio Inc
- ABIONYX Pharma SA
- Addpharma Inc
- Afimmune Biopharma Ltd
- Akcea Therapeutics Inc
- Akeso Inc
- Amarin Corp Plc
- Arrakis Therapeutics Inc
- Arrowhead Pharmaceuticals Inc
- AstraZeneca Plc
- AVVA Pharmaceuticals AG
- Beijing Mabworks Biotech Co Ltd
- Bio-Thera Solutions Ltd
- BioRestorative Therapies Inc
- Boryung Pharmaceutical Co Ltd
- Cardax Inc
- Celltrion Inc
- Centaurus Therapeutics Inc
- Centeer BioTherapeutics Ltd Co
- Chong Kun Dang Pharmaceutical Corp
- CMG Pharmaceutical Co Ltd
- Corvidia Therapeutics Inc
- CVI Pharmaceuticals US Inc
- Daewon Pharmaceutical Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Delivra Corp
- Dicerna Pharmaceuticals Inc
- DongKoo Bio & Pharma Co Ltd
- Eccogene (Shanghai) Co Ltd
- Eli Lilly and Co
- Esperion Therapeutics Inc
- Genu Pharma Co Ltd
- Gilead Sciences Inc
- Golden Biotechnology Corp
- Guangzhou Jiayue Pharmaceutical Technology Co Ltd
- Halo Therapeutics Ltd
- Handok Inc
- Hanmi Pharmaceuticals Co Ltd
- HK inno.N Corp
- Huons Co Ltd
- Ildong Pharmaceutical Co Ltd
- Inovio Pharmaceuticals Inc
- Inversago Pharma Inc
- Japan Tobacco Inc
- Jeil Pharmaceutical Co Ltd
- Jenrin Discovery Inc
- Jiangsu Hengrui Medicine Co Ltd
- JW Pharmaceutical Corp
- Korea United Pharm Inc
- Kotobuki Pharmaceutical Co Ltd
- Kowa Co Ltd
- Kuhnil Pharmaceutical Co Ltd
- Kyorin Pharmaceutical Co Ltd
- Kyttaro Ltd
- Kyung Dong Co Ltd
- Les Laboratoires Servier SAS
- Liid Pharmaceuticals Inc
- LipimetiX Development Inc
- Lyndra Therapeutics Inc.
- Madrigal Pharmaceuticals Inc
- Matinas BioPharma Holdings Inc
- MD Healthcare Inc
- Mochida Pharmaceutical Co Ltd
- Navipharm Co Ltd
- NewAmsterdam Pharma BV
- Nippon Chemiphar Co Ltd
- Nissan Chemical Corp
- NorthSea Therapeutics BV
- NovalGen Ltd
- Novartis AG
- Nubiyota LLC
- NuSirt Biopharma Inc
- Omeros Corp
- Orient Pharma Co Ltd
- Pharmena SA
- Regeneron Pharmaceuticals Inc
- Rivus Pharmaceuticals Inc
- Saliogen Therapeutics Inc
- Sequor Pharmaceuticals LLC
- Shanghai Junshi Bioscience Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Sirnaomics Ltd
- SJT Molecular Research SL
- Staten Biotechnology BV
- Suzhou Ribo Life Sciences Co Ltd
- Sveikatal Inc
- Synokem Pharmaceuticals Ltd
- Tetranov International Inc
- Torrent Pharmaceuticals Ltd
- Viking Therapeutics Inc
- Yooyoung Pharm Co Ltd
- Yungjin Pharm Co Ltd
- Zydus Lifesciences Ltd
- Dyslipidemia – Drug Profiles
- (amlodipine + pitavastatin + valsartan) – Drug Profile
- (amlodipine + rosuvastatin + valsartan) – Drug Profile
- (amlodipine besylate + ezetimibe + rosuvastatin calcium + valsartan) – Drug Profile
- (amlodipine besylate + rosuvastatin calcium + telmisartan) – Drug Profile
- (amlodipine besylate + rosuvastatin calcium + valsartan) – Drug Profile
- (amlodipine besylate + valsartan) + atorvastatin calcium – Drug Profile
- (amlodipine maleate + rosuvastatin calcium + telmisartan) – Drug Profile
- (atorvastatin + amlodipine + candesartan) – Drug Profile
- (atorvastatin + ezetimibe) – Drug Profile
- (atorvastatin + fimasartan) – Drug Profile
- (atorvastatin + omega-3-acid ethyl esters) – Drug Profile
- (atorvastatin calcium + metformin hydrochloride XR) – Drug Profile
- (atorvastatin calcium + perindopril) – Drug Profile
- (ezetimibe + pitavastatin calcium) – Drug Profile
- (ezetimibe + rosuvastatin + telmisartan) – Drug Profile
- (metformin hydrochloride + rosuvastatin calcium) – Drug Profile
- (rosuvastatin + teneligliptin) – Drug Profile
- 1PC-111 – Drug Profile
- AC-261066 – Drug Profile
- AD-103 – Drug Profile
- AD-104 – Drug Profile
- AD-110 – Drug Profile
- AD-201 – Drug Profile
- AD-202 – Drug Profile
- AD-205 – Drug Profile
- AD-207 – Drug Profile
- AD-210 – Drug Profile
- AD-216 – Drug Profile
- AD-217 – Drug Profile
- AD-218 – Drug Profile
- AD-220 – Drug Profile
- AEM-28 – Drug Profile
- AEM-2814 – Drug Profile
- Anti-ANGPTL3/8 Antibody Program – Drug Profile
- Antisense oligonucleotide for Hypertriglyceridemia – Drug Profile
- Antisense Oligonucleotide to Inhibit NCSTN for Hypertriglyceridemia – Drug Profile
- antroquinonol – Drug Profile
- APOC3 (dyslipidemia) – Drug Profile
- AROANG-3 – Drug Profile
- AROAPOC-3 – Drug Profile
- atorvastatin + CDRI 80/574 – Drug Profile
- AZD-8233 – Drug Profile
- azilsartan + rosuvastatin – Drug Profile
- BAT-6024 – Drug Profile
- BR-1006 – Drug Profile
- BR-1008 – Drug Profile
- bulevirtide – Drug Profile
- CBT-1420D – Drug Profile
- CBT-1430E – Drug Profile
- CDR-267F018 – Drug Profile
- CDX-101 – Drug Profile
- CER-209 – Drug Profile
- CKD-331 – Drug Profile
- CKD-348 – Drug Profile
- CKD-385 – Drug Profile
- CKD-386 – Drug Profile
- CKD-508 – Drug Profile
- Clerodane diterpene – Drug Profile
- CMG-190303 – Drug Profile
- COR-003 – Drug Profile
- CTK-2002 – Drug Profile
- CTL-09 – Drug Profile
- CVILM-001 – Drug Profile
- cynarine – Drug Profile
- DC-371739 – Drug Profile
- DKB-15003 – Drug Profile
- Drug to Agonize THRB for Dyslipidemia and Non Alcoholic Steatohepatitis (NASH) – Drug Profile
- DW-1125 – Drug Profile
- DW-4301 – Drug Profile
- DWJ-1451 – Drug Profile
- DWJ-1506 – Drug Profile
- DWJ-1507 – Drug Profile
- ebronucimab – Drug Profile
- ecostatin – Drug Profile
- epeleuton – Drug Profile
- evinacumab – Drug Profile
- Gene Therapy for Hypertriglyceridemia – Drug Profile
- Gene Therapy to Inhibit PCSK9 for Hyperlipidemia – Drug Profile
- Gene Therapy to Replace ApoC2 for Hypertriglyceridemia – Drug Profile
- HCP-1105 – Drug Profile
- HL-1550 – Drug Profile
- HLTX-3 – Drug Profile
- HU-6 – Drug Profile
- HUC-2396 – Drug Profile
- icosapent ethyl – Drug Profile
- IMMH-007 – Drug Profile
- inclisiran – Drug Profile
- INV-202 – Drug Profile
- JD-2000 Series – Drug Profile
- JD-5000 Series – Drug Profile
- JD-6000 Series – Drug Profile
- JTP-109192 – Drug Profile
- KI-1101 – Drug Profile
- KI-1102 – Drug Profile
- KI-1114 – Drug Profile
- KI-1121 – Drug Profile
- KI-1122 – Drug Profile
- KI-1124 – Drug Profile
- KI-1125 – Drug Profile
- KI-1126 – Drug Profile
- KI-3106 – Drug Profile
- KI-3121 – Drug Profile
- KKM-1201 – Drug Profile
- KT-6971 – Drug Profile
- leucine + niacin – Drug Profile
- liothyronine sodium – Drug Profile
- LTW-980 – Drug Profile
- LY-3475766 – Drug Profile
- LY-3561774 – Drug Profile
- MDH-201 – Drug Profile
- MET-2 – Drug Profile
- MET-5 – Drug Profile
- MGL-3745 – Drug Profile
- MIL-86 – Drug Profile
- MN-002 – Drug Profile
- NC-2400 – Drug Profile
- Next-Generation ACL Inhibitor – Drug Profile
- NovalGen-VI – Drug Profile
- obicetrapib – Drug Profile
- olezarsen sodium – Drug Profile
- Oligonucleotide to Activate MicroRNA-30c for Atherosclerosis and Hyperlipidemia – Drug Profile
- omega-3-pentaenoic acids – Drug Profile
- ongericimab – Drug Profile
- pegozafermin – Drug Profile
- pelacarsen sodium – Drug Profile
- pemafibrate – Drug Profile
- pitavastatin CR – Drug Profile
- Recombinant Protein for Hypertriglyceridemia – Drug Profile
- REGN-1001 – Drug Profile
- rosuvastatin ER – Drug Profile
- S-0130431 – Drug Profile
- SAL-003 – Drug Profile
- SAL-092 – Drug Profile
- saroglitazar – Drug Profile
- SCM-198 – Drug Profile
- SEFA-1024 – Drug Profile
- SHR-1209 – Drug Profile
- SJT-4a – Drug Profile
- SJT-7a – Drug Profile
- Small Molecule for Atherosclerosis and Hyperlipidemia – Drug Profile
- Small Molecule for Cardiovascular and Metabolic Diseases – Drug Profile
- Small Molecule for Hyperlipidemia – Drug Profile
- Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia – Drug Profile
- Small Molecule to Antagonize GABAA Receptor for Metabolic, Gastrointestinal and Cardiovascular Disorders – Drug Profile
- Small Molecule to Inhibit CETP for Dyslipidemia – Drug Profile
- Small Molecule to Inhibit DGAT1 for Hyperlipidemia – Drug Profile
- Small Molecule to Inhibit HSL for Dyslipidemia – Drug Profile
- Small Molecule to Target GPR146 for Metabolic Disorders – Drug Profile
- Small Molecules for Dyslipidemia – Drug Profile
- Small Molecules for Hypercholesterolemia and Dyslipidemia – Drug Profile
- Small Molecules to Agonize PPAR Alpha for Dyslipidemia and Non-Alcoholic Steatohepatitis – Drug Profile
- Small Molecules to Inhibit DEGS1 for Dyslipidemia, Non-Alcoholic Steatohepatitis and Type 2 Diabetes – Drug Profile
- Small Molecules to Inhibit FABP1 for Hyperlipidemia and Fatty Liver Disease – Drug Profile
- Small Molecules to Inhibit PCSK9 for Dyslipidemia, Cardiovascular Disease and Familial Hypercholesterolemia – Drug Profile
- Small Molecules to Inhibit PCSK9 for Hyperlipidemia – Drug Profile
- SR-043 – Drug Profile
- SR-044 – Drug Profile
- SR-045 – Drug Profile
- STP-133G – Drug Profile
- STT-5058 – Drug Profile
- ThermoStem – Drug Profile
- TRC-150094 – Drug Profile
- TRIA-662 – Drug Profile
- UI-014 – Drug Profile
- UI-044 – Drug Profile
- UI-061 – Drug Profile
- VK-1430 – Drug Profile
- volanesorsen sodium – Drug Profile
- YPI-008 – Drug Profile
- YYC-506 – Drug Profile
- ZYH-7 – Drug Profile
- Dyslipidemia – Dormant Projects
- Dyslipidemia – Discontinued Products
- Dyslipidemia – Product Development Milestones
- Featured News & Press Releases
- Feb 25, 2022: Arrowhead concludes enrolment in Phase IIb mixed dyslipidemia trial
- Dec 22, 2021: Akeso: Early completion of patient enrollment of Ebronucimab (PCSK9 monoclonal antibody, AK102) in a phase III clinical trial for primary hypercholesterolemia and mixed hyperlipidemia in China
- Nov 15, 2021: Arrowhead presents new clinical data on ARO-APOC3 at AHA 2021
- Nov 15, 2021: NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial
- Nov 03, 2021: Ionis begins clinical trial of severe hypertriglyceridemia medicine
- Nov 02, 2021: Rivus reports positive data from trial of cardiometabolic disease therapy
- Sep 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of ARO-APOC3 for treatment of mixed dyslipidemia
- Jul 28, 2021: NewAmsterdam Pharma reports positive results from phase 2 study of Oral Obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins
- Jul 06, 2021: Novartis announces complete response resubmission for inclisiran new drug application
- Jun 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-ANG3 for treatment of mixed dyslipidemia
- Jun 03, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-APOC3 for treatment of severe hypertriglyceridemia
- May 16, 2021: tctMD: Evinacumab lowers triglycerides in severe hypertriglyceridemia
- Mar 22, 2021: JW Pharmaceutical: Proving the effect of improving lipids as a result of phase 3 clinical trial of RivaroJet 'NDA application'
- Mar 01, 2021: Arrowhead Pharmaceuticals files IND to begin phase 2b study of ARO-APOC3 in patients with severe hypertriglyceridemia
- Feb 01, 2021: Matinas BioPharma announces topline results from ENHANCE-IT study of LYPDISO against Vascepa
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Dyslipidemia, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Universities/Institutes, 2022
- Table 8: Products under Development by Companies, 2022
- Table 9: Products under Development by Companies, 2022 (Contd..1)
- Table 10: Products under Development by Companies, 2022 (Contd..2)
- Table 11: Products under Development by Companies, 2022 (Contd..3)
- Table 12: Products under Development by Companies, 2022 (Contd..4)
- Table 13: Products under Development by Companies, 2022 (Contd..5)
- Table 14: Products under Development by Companies, 2022 (Contd..6)
- Table 15: Products under Development by Companies, 2022 (Contd..7)
- Table 16: Products under Development by Companies, 2022 (Contd..8)
- Table 17: Products under Development by Universities/Institutes, 2022
- Table 18: Number of Products by Stage and Target, 2022
- Table 19: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 20: Number of Products by Stage and Mechanism of Action, 2022
- Table 21: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 22: Number of Products by Stage and Route of Administration, 2022
- Table 23: Number of Products by Stage and Molecule Type, 2022
- Table 24: Dyslipidemia – Pipeline by 89bio Inc, 2022
- Table 25: Dyslipidemia – Pipeline by ABIONYX Pharma SA, 2022
- Table 26: Dyslipidemia – Pipeline by Addpharma Inc, 2022
- Table 27: Dyslipidemia – Pipeline by Afimmune Biopharma Ltd, 2022
- Table 28: Dyslipidemia – Pipeline by Akcea Therapeutics Inc, 2022
- Table 29: Dyslipidemia – Pipeline by Akeso Inc, 2022
- Table 30: Dyslipidemia – Pipeline by Amarin Corp Plc, 2022
- Table 31: Dyslipidemia – Pipeline by Arrakis Therapeutics Inc, 2022
- Table 32: Dyslipidemia – Pipeline by Arrowhead Pharmaceuticals Inc, 2022
- Table 33: Dyslipidemia – Pipeline by AstraZeneca Plc, 2022
- Table 34: Dyslipidemia – Pipeline by AVVA Pharmaceuticals AG, 2022
- Table 35: Dyslipidemia – Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
- Table 36: Dyslipidemia – Pipeline by Bio-Thera Solutions Ltd, 2022
- Table 37: Dyslipidemia – Pipeline by BioRestorative Therapies Inc, 2022
- Table 38: Dyslipidemia – Pipeline by Boryung Pharmaceutical Co Ltd, 2022
- Table 39: Dyslipidemia – Pipeline by Cardax Inc, 2022
- Table 40: Dyslipidemia – Pipeline by Celltrion Inc, 2022
- Table 41: Dyslipidemia – Pipeline by Centaurus Therapeutics Inc, 2022
- Table 42: Dyslipidemia – Pipeline by Centeer BioTherapeutics Ltd Co, 2022
- Table 43: Dyslipidemia – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
- Table 44: Dyslipidemia – Pipeline by CMG Pharmaceutical Co Ltd, 2022
- Table 45: Dyslipidemia – Pipeline by Corvidia Therapeutics Inc, 2022
- Table 46: Dyslipidemia – Pipeline by CVI Pharmaceuticals US Inc, 2022
- Table 47: Dyslipidemia – Pipeline by Daewon Pharmaceutical Co Ltd, 2022
- Table 48: Dyslipidemia – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 49: Dyslipidemia – Pipeline by Daiichi Sankyo Co Ltd, 2022
- Table 50: Dyslipidemia – Pipeline by Delivra Corp, 2022
- Table 51: Dyslipidemia – Pipeline by Dicerna Pharmaceuticals Inc, 2022
- Table 52: Dyslipidemia – Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
- Table 53: Dyslipidemia – Pipeline by Eccogene (Shanghai) Co Ltd, 2022
- Table 54: Dyslipidemia – Pipeline by Eli Lilly and Co, 2022
- Table 55: Dyslipidemia – Pipeline by Esperion Therapeutics Inc, 2022
- Table 56: Dyslipidemia – Pipeline by Genu Pharma Co Ltd, 2022
- Table 57: Dyslipidemia – Pipeline by Gilead Sciences Inc, 2022
- Table 58: Dyslipidemia – Pipeline by Golden Biotechnology Corp, 2022
- Table 59: Dyslipidemia – Pipeline by Guangzhou Jiayue Pharmaceutical Technology Co Ltd, 2022
- Table 60: Dyslipidemia – Pipeline by Halo Therapeutics Ltd, 2022
- Table 61: Dyslipidemia – Pipeline by Handok Inc, 2022
- Table 62: Dyslipidemia – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
- Table 63: Dyslipidemia – Pipeline by HK inno.N Corp, 2022
- Table 64: Dyslipidemia – Pipeline by Huons Co Ltd, 2022
- Table 65: Dyslipidemia – Pipeline by Ildong Pharmaceutical Co Ltd, 2022
- Table 66: Dyslipidemia – Pipeline by Inovio Pharmaceuticals Inc, 2022
- Table 67: Dyslipidemia – Pipeline by Inversago Pharma Inc, 2022
- Table 68: Dyslipidemia – Pipeline by Japan Tobacco Inc, 2022
- Table 69: Dyslipidemia – Pipeline by Jeil Pharmaceutical Co Ltd, 2022
- Table 70: Dyslipidemia – Pipeline by Jenrin Discovery Inc, 2022
- Table 71: Dyslipidemia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 72: Dyslipidemia – Pipeline by JW Pharmaceutical Corp, 2022
- Table 73: Dyslipidemia – Pipeline by Korea United Pharm Inc, 2022
- Table 74: Dyslipidemia – Pipeline by Kotobuki Pharmaceutical Co Ltd, 2022
- Table 75: Dyslipidemia – Pipeline by Kowa Co Ltd, 2022
- Table 76: Dyslipidemia – Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
- Table 77: Dyslipidemia – Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
- Table 78: Dyslipidemia – Pipeline by Kyttaro Ltd, 2022
- Table 79: Dyslipidemia – Pipeline by Kyung Dong Co Ltd, 2022
- Table 80: Dyslipidemia – Pipeline by Les Laboratoires Servier SAS, 2022
- Table 81: Dyslipidemia – Pipeline by Liid Pharmaceuticals Inc, 2022
- Table 82: Dyslipidemia – Pipeline by LipimetiX Development Inc, 2022
- Table 83: Dyslipidemia – Pipeline by Lyndra Therapeutics Inc., 2022
- Table 84: Dyslipidemia – Pipeline by Madrigal Pharmaceuticals Inc, 2022
- Table 85: Dyslipidemia – Pipeline by Matinas BioPharma Holdings Inc, 2022
- Table 86: Dyslipidemia – Pipeline by MD Healthcare Inc, 2022
- Table 87: Dyslipidemia – Pipeline by Mochida Pharmaceutical Co Ltd, 2022
- Table 88: Dyslipidemia – Pipeline by Navipharm Co Ltd, 2022
- Table 89: Dyslipidemia – Pipeline by NewAmsterdam Pharma BV, 2022
- Table 90: Dyslipidemia – Pipeline by Nippon Chemiphar Co Ltd, 2022
- Table 91: Dyslipidemia – Pipeline by Nissan Chemical Corp, 2022
- Table 92: Dyslipidemia – Pipeline by NorthSea Therapeutics BV, 2022
- Table 93: Dyslipidemia – Pipeline by NovalGen Ltd, 2022
- Table 94: Dyslipidemia – Pipeline by Novartis AG, 2022
- Table 95: Dyslipidemia – Pipeline by Nubiyota LLC, 2022
- Table 96: Dyslipidemia – Pipeline by NuSirt Biopharma Inc, 2022
- Table 97: Dyslipidemia – Pipeline by Omeros Corp, 2022
- Table 98: Dyslipidemia – Pipeline by Orient Pharma Co Ltd, 2022
- Table 99: Dyslipidemia – Pipeline by Pharmena SA, 2022
- Table 100: Dyslipidemia – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 101: Dyslipidemia – Pipeline by Rivus Pharmaceuticals Inc, 2022
- Table 102: Dyslipidemia – Pipeline by Saliogen Therapeutics Inc, 2022
- Table 103: Dyslipidemia – Pipeline by Sequor Pharmaceuticals LLC, 2022
- Table 104: Dyslipidemia – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 105: Dyslipidemia – Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
- Table 106: Dyslipidemia – Pipeline by Sirnaomics Ltd, 2022
- Table 107: Dyslipidemia – Pipeline by SJT Molecular Research SL, 2022
- Table 108: Dyslipidemia – Pipeline by Staten Biotechnology BV, 2022
- Table 109: Dyslipidemia – Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
- Table 110: Dyslipidemia – Pipeline by Sveikatal Inc, 2022
- Table 111: Dyslipidemia – Pipeline by Synokem Pharmaceuticals Ltd, 2022
- Table 112: Dyslipidemia – Pipeline by Tetranov International Inc, 2022
- Table 113: Dyslipidemia – Pipeline by Torrent Pharmaceuticals Ltd, 2022
- Table 114: Dyslipidemia – Pipeline by Viking Therapeutics Inc, 2022
- Table 115: Dyslipidemia – Pipeline by Yooyoung Pharm Co Ltd, 2022
- Table 116: Dyslipidemia – Pipeline by Yungjin Pharm Co Ltd, 2022
- Table 117: Dyslipidemia – Pipeline by Zydus Lifesciences Ltd, 2022
- Table 118: Dyslipidemia – Dormant Projects, 2022
- Table 119: Dyslipidemia – Dormant Projects, 2022 (Contd..1)
- Table 120: Dyslipidemia – Dormant Projects, 2022 (Contd..2)
- Table 121: Dyslipidemia – Dormant Projects, 2022 (Contd..3)
- Table 122: Dyslipidemia – Dormant Projects, 2022 (Contd..4)
- Table 123: Dyslipidemia – Dormant Projects, 2022 (Contd..5)
- Table 124: Dyslipidemia – Dormant Projects, 2022 (Contd..6)
- Table 125: Dyslipidemia – Dormant Projects, 2022 (Contd..7)
- Table 126: Dyslipidemia – Dormant Projects, 2022 (Contd..8)
- Table 127: Dyslipidemia – Dormant Projects, 2022 (Contd..9)
- Table 128: Dyslipidemia – Dormant Projects, 2022 (Contd..10)
- Table 129: Dyslipidemia – Dormant Projects, 2022 (Contd..11)
- Table 130: Dyslipidemia – Dormant Projects, 2022 (Contd..12)
- Table 131: Dyslipidemia – Dormant Projects, 2022 (Contd..13)
- Table 132: Dyslipidemia – Discontinued Products, 2022
- Table 133: Dyslipidemia – Discontinued Products, 2022 (Contd..1)
- Table 134: Dyslipidemia – Discontinued Products, 2022 (Contd..2)
- Table 135: Dyslipidemia – Discontinued Products, 2022 (Contd..3)
- List of Figures
- Figure 1: Number of Products under Development for Dyslipidemia, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.